Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitazoxanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitazoxanide SCHEMBL5055353 | 1.00 | STAT3 (1.00) | STAT3NPC1RAB9AMEN1KMT2A | |
| Nitazoxanide SCHEMBL29373905 | 1.00 | STAT3 (1.00) | STAT3NPC1RAB9AMEN1KMT2A | |
| Nitazoxanide SCHEMBL28195534 | 0.99 | STAT3 (0.98) | STAT3NPC1RAB9AMEN1KMT2A | |
| Nitazoxanide SCHEMBL27651337 | 0.99 | STAT3 (0.98) | STAT3NPC1RAB9AMEN1KMT2A | |
| Nitazoxanide SCHEMBL19512160 | 0.97 | STAT3 (0.94) | STAT3NPC1RAB9AMEN1KMT2A | |
| Nitazoxanide SCHEMBL28333130 | 0.95 | STAT3 (0.90) | STAT3NPC1RAB9AMEN1KMT2A | |
| Nitazoxanide SCHEMBL19449896 | 0.92 | STAT3 (0.86) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16572481 | 0.91 | NPC1 (0.83) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29056942 | 0.91 | STAT3 (0.83) | STAT3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL30142740 | 0.90 | MEN1 (0.82) | STAT3NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11246 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075486-A | Application of nitazoxanide and in-vivo metabolite tizoxanide thereof in preparing medicines for treating feline parvovirus infection | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| CN-122028921-A | Use of TMED10 as target in the treatment of inflammation | 清华大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260124182-A1 | NITAZOXANIDE FOR THE TREATMENT OF HEPATIC IMPAIRMENT | GENFIT (FR) | 2026-05-07 | — | — | US | claimed |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-1069911-A1 | A NOVEL NITROREDUCTASE AND THERAPEUTIC USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 2001-01-24 | — | — | EP | claimed |
| EP-1043978-A1 | PHOSPHOLIPID-COATED MICROCRYSTALS FOR THE SUSTAINED RELEASE OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR MANUFACTURE AND USE | IDEXX LABORATORIES, INC. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-2000027369-A1 | PHOSPHOLIPID-COATED MICROCRYSTALS FOR THE SUSTAINED RELEASE OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR MANUFACTURE AND USE | IDEXX LABORATORIES, INC. (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000019964-A2 | NOVEL COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PROTOZOAL DISEASE | NEW ACE RESEARCH COMPANY (US) | 2000-04-13 | — | — | WO | claimed |
| WO-1999051270-A1 | A NOVEL NITROREDUCTASE AND THERAPEUTIC USES THEREFOR | DALHOUSIE UNIVERSITY (CA) | 1999-10-14 | — | — | WO | claimed |
| US-5935591-A | Method for treatment of equine protozoal myeloencephalitis with thiazolides | ROMARK LABORATORIES, L.C. (US) | 1999-08-10 | — | — | US | claimed |
| US-5886013-A | Antiviral composition | ROMARK LABORATORIES, L.C. (US) | 1999-03-23 | — | — | US | claimed |
| WO-1996019220-A1 | A COMBINATION PRODUCT COMPRISING NITAZOXANIDE AND AN ANTI-ULCER AGENT | LAUTERAL LIMITED (IE) | 1996-06-27 | — | — | WO | claimed |
| WO-1996019232-A1 | COMBINATIONS OF RANITIDINE HYDROCHLORIDE-FORM 1 AND BISMUTH COMPOUNDS | LAUTERAL LIMITED (IE) | 1996-06-27 | — | — | WO | claimed |
| US-4315018-A | Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives | ROMARK LABORATORIES, L.C. | 1982-02-09 | — | — | US | claimed |